Atorvastatin: safety and tolerability (Q37765562)

22 August 2017

1 reference

title

Atorvastatin: safety and tolerability (English)

1 reference

22 August 2017

Dimitri P Mikhailidis

series ordinal

4

object named as

Dimitri P Mikhailidis

1 reference

22 August 2017

Vasilios G Athyros

1

1 reference

22 August 2017

Konstantinos Tziomalos

series ordinal

2

1 reference

22 August 2017

Asterios Karagiannis

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Drug Safety

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

4

1 reference

22 August 2017

667-674

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Atorvastatin: a safety and tolerability profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Pleiotropic effects of statins--clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Statin safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Statin-induced myopathy: the two faces of Janus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Statins and myotoxicity: a therapeutic limitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Combination therapy for dyslipidemia: safety and regulatory considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Etiology and frequency of rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Does simvastatin cause more myotoxicity compared with other statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Safety of high-dose atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Risk factors for statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Targeting vascular risk in patients with metabolic syndrome but without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.495385

10.1517/14740338.2010.495385

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference